1 min read
CPI-1612 is a pretty efficient-looking EP300/CBP histone acetyltransferase (HAT) inhibitor tool compound with demonstrated activity in a xenograft model and good higher species PK. While epigenetics targets like HATs have been hot this decade, many programs have run into tolerability challenges and/or difficulty identifying activity biomarkers. It doesn’t look like CPI-1612 entered development so it’s likely the program encountered similar issues. While irrelevant for a tool compound, it’s interesting that they were able to abrogate in vitro hERG activity in an early indole series by switching to the 2-amidopyridine scaffold in CPI-1612.